Columbia University Department of Psychiatry, New York, NY, United States.
Columbia University Department of Psychiatry, New York, NY, United States; New York State Psychiatric Institute, 1051 Riverside Drive, Unit #51, New York, NY, 10032, United States.
J Affect Disord. 2021 Mar 1;282:1143-1152. doi: 10.1016/j.jad.2020.12.174. Epub 2020 Dec 30.
Triple chronotherapy (wake night [one night without sleep], sleep phase advance, and early morning bright light exposure) demonstrated rapid efficacy primarily in bipolar depression, but has not been as well studied in unipolar depression. Our primary hypothesis is that triple chronotherapy is associated with a significantly greater Week 1 remission rate compared to the alternative protocol.
Unipolar depressed, nonpsychotic adult outpatients were randomized to triple chronotherapy or an alternative protocol (assigned sleep times without wake night, bright light exposure with blue-green wavelengths filtered out). Symptoms were assessed with Structured Interview Guide for Hamilton Depression Rating Scale with Atypical Supplement (SIGH-ADS) at each visit and a modified form (m-SIGH) daily for the first week. Response was defined as a 50% decrease in m-SIGH score, and remission as m-SIGH≤7, modified Clinical Global Impression-Improvement (m-CGI-I)≤2, and no depressed mood on m-SIGH.
44 patients (84.1% major depressive disorder, 75.0% persistent depressive disorder; 54.5% female; age mean±SD 38.3 ± 15.2 years) were randomized to triple chronotherapy (N = 22) or an alternative protocol (N = 22). Week 1 remission rate was numerically higher but not statistically significant in the triple chronotherapy versus alternative protocol group (25.0% vs. 6.7%, Chi-square=1.76, df=1, p = 0.294). m-SIGH scores and response and remission rates on Days 2-7 were numerically improved without reaching statistical significance in the triple chronotherapy versus alternative protocol group.
Predominantly white, educated sample.
This small pilot study demonstrated triple chronotherapy's feasibility and tolerability in unipolar depressed outpatients. Larger randomized trials are warranted to further characterize acute and long-term efficacy.
三重时间疗法(熬夜一晚[不睡觉]、睡眠相位提前和清晨强光暴露)在双相抑郁症中显示出快速疗效,但在单相抑郁症中的研究还不够充分。我们的主要假设是,三重时间疗法与替代方案相比,在第 1 周的缓解率上有显著提高。
非精神病单相抑郁成年门诊患者被随机分配到三重时间疗法或替代方案(分配没有熬夜的睡眠时间,用过滤掉蓝绿光的强光暴露)。每次就诊时使用 Hamilton 抑郁评定量表的结构访谈指南(带非典型补充)(SIGH-ADS)评估症状,第 1 周每天使用简化版 SIGH-ADS(m-SIGH)进行评估。反应定义为 m-SIGH 评分降低 50%,缓解定义为 m-SIGH≤7、改良临床总体印象-改善(m-CGI-I)≤2、m-SIGH 无抑郁情绪。
44 名患者(84.1%为重度抑郁症,75.0%为持续性抑郁症;54.5%为女性;年龄平均值±标准差为 38.3±15.2 岁)被随机分配到三重时间疗法组(n=22)或替代方案组(n=22)。第 1 周的缓解率在三重时间疗法组略高,但无统计学意义(25.0%比 6.7%,卡方=1.76,自由度=1,p=0.294)。在三重时间疗法组与替代方案组之间,m-SIGH 评分和第 2-7 天的反应和缓解率均有所改善,但无统计学意义。
主要为白人、受过教育的样本。
这项小型先导研究证明了三重时间疗法在单相抑郁门诊患者中的可行性和耐受性。需要更大规模的随机试验来进一步确定其急性和长期疗效。